Raymond James Financial upgraded Aktis Oncology, Inc. to a strong-buy rating on June 17, 2026.
6 reports, 2 independent
Updated Oct 10
Gone quiet
- Reports
- 6
- Developments
- 2
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Raymond James Financial upgraded Aktis Oncology, Inc. to a strong-buy rating on June 17, 2026.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Numerous investment firms initiated coverage or boosted stakes in Aktis Oncology.1 source
Raymond James Financial upgraded Aktis Oncology to a strong-buy rating.1 source
Keep exploring
The entities involved
-
Raymond James Financial
American Investment Bank and Financial Services Firm